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A number of recent studies have found that the risk
of breast cancer is augmented by the use of hormonal
treatment (HT), as a combined therapy with oestrogen
and progestins (EPT). Nevertheless, the amplitude of the
risk and the mortality risk remain a matter of debate.
Worldwide, an increase in peri- and post-menopausal
breast cancer incidence has been noted when compared
with the incidence noted 50 years ago. This increase can
be due to the changes in parity and to the age at ﬁrst
pregnancy, to the increase in mammographic screening,
to the use of hormonal contraception with high dosages,
and due to the use of HT after the menopause.
The risk, attributed to EPT, has been associated with
current use and neither the dose, type of administration,
type of progestin or therapy schedule (continuous
combined or continuous sequential) have modiﬁed these
ﬁndings. This risk seems to be independent of other risk
factors of breast cancer (such as parity, age at menarche,
age at ﬁrst full-term pregnancy and family history of
breast cancer), except for weight. Lean women show a
higher risk than other women [1,2].
However,the overall cancer incidence after HT use is
not increased due to the fact that HT reduces the risk of
colon cancer and, possibly, smoking-related cancers
[3,4]. Looking at women using EPT, the strong eﬀect on
breast cancer may lead to a slight increase in the total
cancer incidence, although risk reductions can be seen
for some tumour sites.
Studies suggested that the breast cancer that develops
in association with HT is of a low malignant grade.
These tumours have a better prognosis and this implies
that the development of each tumour may follow, at
least partly, a distinct pathway of evolution, according
to the parent’s age, tumour proliferation rate and cell
biology at the moment of initiation [5].
However, in the most recent study, the Women’s
Health Initiative (WHI) randomised trial, the breast
cancer type associated with EPT use was less favourable
(tumours were larger and at a more advanced stage)
than in the control group not using HT; oestrogen plus
progestin may stimulate breast cancer growth and the
higher breast density can hamper breast cancer diag-
nosis [6,7]. In some studies, it is suggested that the his-
tological breast cancer type, lobular carcinoma, has a
stronger risk relationship with hormone replacement
therapy (HRT) use than ductal carcinoma.
If we consider mortality, there was no diﬀerence in
the WHI study between the treatment and placebo
groups, while in some observational studies, the sur-
vival rate was better in female users of HT, in-
dependent of mammographic screening. These studies
may have inherent biases that aﬀect their interpreta-
tion, so there is a need for more good prospective
survival data.
Whether there is a risk of breast cancer after use of
oestrogen only (ET) or use of tibolone is less clear.
The large Million Women Study in the United
Kingdom (UK) [8] suggests that there is a slight increase
in risk after the use of oestrogens or tibolone, while
previous studies have not clearly shown that. The small
number of tibolone users so far included in cohort
studies may inherently carry high-risk factors for breast
cancer, such as a family history of the disease. Assuming
that a third of women using tibolone have a family
history compatible with breast cancer, the Relative Risk
(RR) for the whole group should be 1.33. However,
results regarding tibolone, in particular, are as yet, dif-
ﬁcult, to interpret.
For all HRTs, as well as for tibolone, results can be
inﬂuenced by some biases (information, surveillance,
recall); the use of mammographic screening and the type
of instrument used to collect exposure information may
impact upon the magnitude of these biases.
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In summary, the use of progestin-containing HTs is
associated with quite a high risk of breast cancer and the
risk increases with a longer duration of use. There is
little evidence as yet to suggest that there is a large dif-
ference in breast cancer risk between combined con-
tinuous and combined sequential therapy. The risk
association disappears after 5 years of non-use.
Oestrogen use only or treatment with tibolone is as-
sociated with a much lower risk, if any.
In the future, further results of randomised controlled
trials (RCTs) are needed but, meanwhile, it may be pos-
sible to assess breast cancer risk in associationwithHTby
use of surrogate markers of breast cancer, such as breast
density or breast epithelial proliferation. Early data from
such studies suggest that increased breast density as a
marker of increased risk is seen in women using combined
oestrogen and progestin therapy. An adverse event from
use of combined HT is that an increased mammographic
density, which is seen in many women, also reduces the
sensitivity of tumour detection by mammography.
Tibolone or oestrogen only therapy do not seem to
substantially increase breast density.
Epithelial proliferation in the breast can also be
considered as an unwanted eﬀect of hormonal treatment
and, possibly, a marker of the breast cancer risk. A
continuous combined EPT signiﬁcantly increases the
proliferation of mammary epithelial cells in post-
menopausal woman [9,10]. With tibolone, there is no
increase of proliferation in the mammary gland of pri-
mates [11]. We are awaiting data in women.
Other markers of breast tolerance to hormone med-
ications, such as breast pain or changes in breast vo-
lume, need to be assessed further in relation to risk.
The surrogatemeasures, such as mammographic breast
density and breast epithelial proliferation (and breast
pain), may predict which agents are associated with a high
breast cancer risk; new agents introduced to the market
should document such eﬀects before approval by govern-
mental agencies. Similarly, studies should be done asses-
sing whether the risk associated with progestin-containing
HTs is concentrated in women showing increased mam-
mographic breast densities, epithelial proliferation in the
breast or tenderness in the breast during therapy.
Our present knowledge on the adverse health events,
especially those associated with EPT use, enable sug-
gestions to be made on how to avoid the breast cancer
risk by using oestrogen therapy only in hysterectomised
women and in women with an intact uterus either using
tibolone or a low-dose progestin intrauterine device
(IUD) with oestrogen given orally or as a patch, but
such association also needs to be investigated further for
its safety proﬁle.
Therapy in women should be individualised and
prescribed at and for an optimal time. Such therapies
given for less than four years have been associated with
negligible increases in breast cancer risk. Preferably, the
patient on such therapy should also be monitored by
mammography to detect signs of increased density.
It is unclear how these data transfer to women who
have already had breast cancer and need HRT. In the
HABITS study (stopped) [12], early data suggest that
progestin-containing therapy is harmful, but this diﬀers
to data reported in the Stockholm study (RR=0.82, 95%
Conﬁdence Interval (CI) 0.35–1.89). This study has also
been stopped due to anticipated diﬃculties in recruit-
ment and compliance. For use of oestrogen only or ti-
bolone deﬁnitive answers are still needed.
Research into safe and eﬀective therapies to relieve
menopausal complaints among women with a personal
history of breast cancer, such as those in LIBERATE
study, has to be continued and supported by physicians
for recruitment.
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